The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Corcept sees 40% growth in 2025 revenue with promising trials, expanded patient base, and strong projections. Read my ...

A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a ...

The firm said it based the decision on the announcement of successful Phase 3 ROSELLA study results in platinum-resistant ovarian cancer. While we acknowledge the potential of Corcept Therapeutics ...

Healthcare & Pharmaceuticalscategory· March 31, 2025 Corcept's ovarian cancer drug cuts disease progression in study, shares jump Corcept Therapeutics said on Monday its experimental drug in ...

Corcept Therapeutics Incorporated’s CORT share price has surged by 7.18%, which has investors questioning if this is right time to sell.

Corcept is studying relacorilant in a variety of serious disorders in addition to ovarian cancer, including endogenous hypercortisolism (Cushing’s syndrome) and prostate cancer. Relacorilant is ...

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 Corcept Therapeutics Incorporated (NASDAQ: CORT), a ...